The startup specializes in Pharma 3.0 drug discovery, utilizing advanced computational methods and machine learning algorithms to identify potential drug candidates more efficiently. This approach addresses the high costs and lengthy timelines associated with traditional pharmaceutical research and development.
Funding
$101.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery is a resource-intensive and time-consuming process, characterized by high costs and lengthy development timelines. Conventional AI-based platforms often require extensive experimental data for training, limiting their effectiveness in the early stages of drug discovery.
Solution
Aqemia is a pharmatech company that accelerates drug discovery by combining quantum-inspired physics with generative AI. Unlike traditional AI platforms, Aqemia's technology generates its own data using unique quantum physics algorithms, enabling it to tackle drug discovery projects from their earliest stages. This approach allows for rapid identification of innovative drug candidates and scales drug discovery projects like tech projects. The company leverages its technology to build a growing pipeline of drug candidates, advancing projects from hit generation to in vivo assays.
Target Audience
Aqemia's primary customers are pharmaceutical companies seeking to accelerate their drug discovery efforts, as well as biotech companies looking to expand their pipelines with novel drug candidates.
Features
- Quantum physics-based algorithms for generating proprietary data, eliminating the need for large experimental datasets.
- Generative AI models guided by physics-based simulations to accelerate the identification of drug candidates.
- Scalable platform enabling rapid screening of vast chemical spaces.
- End-to-end drug discovery pipeline, from target identification to preclinical development.